Director/PDMR Shareholding

RNS Number : 2165U

Dechra Pharmaceuticals PLC

28 November 2013

 



28 November 2013

Dechra Pharmaceuticals PLC

(the "Company")

Director / PDMR Shareholding

The Company announces that on 27 November 2013 the following Directors/PDMRs were granted nil cost options over ordinary shares of 1 pence each in the Company in connection with the Dechra Long Term Incentive Plan 2008 (the "Plan"):

Name of individual	Director/PDMR	Type of award	Number of shares subject to award
Ian Page	Director	Option	129,221
Anne-Francoise Nesmes	Director	Option	66,079
Tony Griffin	Director	Option	34,129
Ed Torr	Director	Option	33,706
Zoe Goulding	PDMR	Option	8,942

The vesting of all the above awards is subject to the achievement of performance targets.  In respect of these grants the performance conditions will be determined by reference to the Company's Earnings per Share ("EPS") and its Total Shareholder Return ("TSR") relative to constituent companies of the FTSE 250 index (excluding investment trusts) over a three year performance period.  Both the EPS and TSR elements will be subject to an additional Return on Capital Employed ("ROCE") performance measure.  If the ROCE performance condition is not met, then the LTIP options will lapse in full.

For further information, please contact:

Zoe Goulding, Company Secretary            

Telephone number: 01606 814730

About Dechra

Dechra is an international specialist veterinary pharmaceuticals business.  Its expertise is in the development, manufacturing and sales and marketing of high quality products exclusively for veterinarians worldwide. Dechra's business is unique as the majority of its products are used to treat medical conditions for which there is no other effective solution or have a clinical or dosing advantage over competitor products.  For more information please visit: www.dechra.com

Trademarks

Dechra and the Dechra "D" logo are registered trademarks of Dechra Pharmaceuticals PLC.

 

END

 

 

RDSNKFDPQBDDNDB